Investing.com -- Bayer AG (ETR:BAYGN) on Wednesday reported a 138% jump in quarterly earnings, lifted by higher margins in its Crop Science division and steady growth in new pharmaceuticals, even as ...

Shares of Bayer BAYRY gained 12.1% after the Solicitor General supported a Supreme Court review of its Roundup weedkiller ...

Bayer AG BAYRY announced that pipeline candidate asundexian met primary efficacy and safety endpoints in late-stage OCEANIC-STROKE Study in secondary stroke prevention. Results from the study showed ...

The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ ...

Health care professionals can have a powerful impact on labeling requirements for drugs by formally petitioning the FDA for ...

The drugs have soared in popularity, with some men taking them for unapproved uses like anti-aging or increasing muscle mass.

In a closely watched case, the U.S. solicitor general urged the Supreme Court to review a controversy over so-called skinny ...

The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...

Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA’s June deadline – 51 dogs ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. Nevertheless, at least as far as ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA has restricted the type ...

Bayer recently reported its third-quarter 2025 results, highlighted by a 20.8% increase in adjusted operating income largely driven by its Crop Science division, as well as new late-breaking Phase III ...